CoChat

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics

Open access

Abstract

The COVID-19 pandemic triggered an unparalleled pursuit of vaccines to induce specific adaptive immunity, based on virus-neutralizing antibodies and T cell responses. Although several vaccines have been developed just a year after SARS-CoV-2 emerged in late 2019, global deployment will take months or even years. Meanwhile, the virus continues to take a severe toll on human life and exact substantial economic costs. Innate immunity is fundamental to mammalian host defense capacity to combat infections. Innate immune responses, triggered by a family of pattern recognition receptors, induce interferons and other cytokines and activate both myeloid and lymphoid immune cells to provide protection against a wide range of pathogens. Epidemiological and biological evidence suggests that the live-attenuated vaccines (LAV) targeting tuberculosis, measles, and polio induce protective innate immunity by a newly described form of immunological memory termed “trained immunity.” An LAV designed to induce adaptive immunity targeting a particular pathogen may also induce innate immunity that mitigates other infectious diseases, including COVID-19, as well as future pandemic threats. Deployment of existing LAVs early in pandemics could complement the development of specific vaccines, bridging the protection gap until specific vaccines arrive. The broad protection induced by LAVs would not be compromised by potential antigenic drift (immune escape) that can render viruses resistant to specific vaccines. LAVs might offer an essential tool to “bend the pandemic curve,” averting the exhaustion of public health resources and preventing needless deaths and may also have therapeutic benefits if used for postexposure prophylaxis of disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2101718118

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. This figure illustrates how a healthy innate immune system protects most people within the population against infections. With an already robust or trained innate immune system, the overwhelming majority of people infected with a new pathogen, such as SARS-CoV-2, are able to eradicate the infection early during the asymptomatic or mildly symptomatic phase of infection. Without prior exposure or vaccination (e.g., with a messenger RNA vaccine), adaptive immunity takes days to weeks to kick in and is often suppressed in severe cases, contributing to a self-perpetuating and injurious hyperinflammatory response. The innate immune system often loses potency with age, certain comorbidities, immunosuppression, and with genetic susceptibility.
Fig. 1. This figure illustrates how a healthy innate immune system protects most people within the population against infections. With an already robust or trained innate immune system, the overwhelming majority of people infected with a new pathogen, such as SARS-CoV-2, are able to eradicate the infection early during the asymptomatic or mildly symptomatic phase of infection. Without prior exposure or vaccination (e.g., with a messenger RNA vaccine), adaptive immunity takes days to weeks to kick in and is often suppressed in severe cases, contributing to a self-perpetuating and injurious hyperinflammatory response. The innate immune system often loses potency with age, certain comorbidities, immunosuppression, and with genetic susceptibility.CC BY-NC-ND · PubMed Central
Fig. 2. The epigenetic mechanism induced by LAVs in innate immune cells and their precursors: methylation and acetylation of histones after vaccination “mark” the gene necessary for host defense, leading to long-term changes in chromatin architecture leading to stronger expression upon subsequent stimuli.
Fig. 2. The epigenetic mechanism induced by LAVs in innate immune cells and their precursors: methylation and acetylation of histones after vaccination “mark” the gene necessary for host defense, leading to long-term changes in chromatin architecture leading to stronger expression upon subsequent stimuli.CC BY-NC-ND · PubMed Central
Fig. 3. Specific vaccines against a new pathogen require extensive preclinical and clinical development and scaling up their production. Because of the urgency, some of the steps can be combined (e.g., phases 1 and 2, or 2 and 3 of clinical trials). On the other hand the existing LAVs only need phase 3 trial of their efficacy. They can either be stockpiled in advance or their manufacture could be ramped up in parallel with testing. Therefore, LAVs can be deployed sooner and used for bridge vaccination to provide (partial) protection and limit the spread of the pandemics until the development of specific vaccines.
Fig. 3. Specific vaccines against a new pathogen require extensive preclinical and clinical development and scaling up their production. Because of the urgency, some of the steps can be combined (e.g., phases 1 and 2, or 2 and 3 of clinical trials). On the other hand the existing LAVs only need phase 3 trial of their efficacy. They can either be stockpiled in advance or their manufacture could be ramped up in parallel with testing. Therefore, LAVs can be deployed sooner and used for bridge vaccination to provide (partial) protection and limit the spread of the pandemics until the development of specific vaccines.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 84 references

Cited by

See all 96

Metadata

Authors
Chumakov, K., Avidan, M. S., Benn, C. S., Bertozzi, S. M., Blatt, L., Chang, A. Y., Jamison, D. T., Khader, S. A., Kottilil, S., Netea, M. G., Sparrow, A., & Gallo, R. C.
Affiliations
  • United States Food and Drug Administration (US)
  • Washington University in St. Louis (US)
  • University of Southern Denmark (DK)
  • University of Washington (US)
  • Global Virus Network (US)
  • University of California, San Francisco (US)
  • University of Maryland, Baltimore (US)
  • University of Bonn (DE)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Gallo, Robert C.
Venue
Proceedings of the National Academy of Sciences
Published
2021-05-18
Volume
118
Issue
21
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3162681080
Cited by
96
References
84
Citations by year
2026: 4 · 2025: 12 · 2024: 14 · 2023: 13 · 2022: 35 · 2021: 18
FWCI
7.46
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc-nd)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
  • Radboud Repository (Radboud University) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords
COVID-19 pandemic, SARS-CoV-2, live attenuated vaccine, trained immunity, innate immunity, pattern recognition receptors, interferon, tuberculosis vaccine, measles vaccine, polio vaccine, pandemic preparedness, antigenic drift, immune evasion, post-exposure prophylaxis, cross-protection
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Immunity, Innate, Immunologic Memory, Vaccines, Vaccines, Attenuated, Adaptive Immunity, Pandemics, Immunity, Heterologous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. https://app.cochat.ai/papers/10.1073/pnas.2101718118
The paper
Chumakov, K., Avidan, M. S., Benn, C. S., Bertozzi, S. M., Blatt, L., Chang, A. Y., Jamison, D. T., Khader, S. A., Kottilil, S., Netea, M. G., Sparrow, A., & Gallo, R. C. (2021). Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2101718118

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.